2017 Press Releases

2017 Press Releases
Home / 2017 Press Releases

2017 Press Releases

Feb-14-2017

Protalix BioTherapeutics Announces Record Date for the 2017 Annual Meeting of Stockholders

CARMIEL, Israel, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that its board of directors approved the record date for the Company’s 2017 Annual Meeting of Stockholders (the “Annual Meeting”) to be held on or about April 10, 2017.  Holders of the Company’s common stock at the close of business on March 15, 2017, the record date, will be entitled to receive notice of, and to vote at, the Annual Meeting. About Protalix BioTherapeu... 
Feb-13-2017

Protalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium™ 2017

Data to be presented in three oral presentations and two poster presentations CARMIEL, Israel, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Company will participate in the 13th Annual WORLDSymposium™ 2017.  The details are as follows: 13th Annual WORLDSymposium™ 2017 February 13 – 17, 2017 Manchester Grand Hyatt, San Diego, CA Oral Presentations: “Characterization of a chemically modified plant cell culture expre... 
Jan-09-2017

Protalix BioTherapeutics Provides Review of 2016 and Strategic Outlook for 2017

Full Switch Plan Initiated and Published by Brazilian Ministry of Health for Gaucher Patients in Brazil Yielding Significant Revenue Stream Fabry Phase III Clinical Trial Underway with Interim Results Expected in 2018 Phase II Clinical Trial for Cystic Fibrosis Positive Interim Data Reported with Full Results Expected During First Quarter of 2017 Phase II Clinical Trial of Oral anti TNF for Ulcerative Colitis Initiated with Results Expected in Second Half of 2017 New Pipeline Candidate... 
Jan-03-2017

Protalix BioTherapeutics Announces Positive Interim Results from Phase II Clinical Trial of alidornase alfa (AIR DNase™) for the Treatment of Cystic Fibrosis

CARMIEL, Israel, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive interim results from the Company’s phase II clinical trial of alidornase alfa for the treatment of Cystic Fibrosis (CF) for the first 13 CF patients enrolled in the study.  Fifteen patients have been enrolled in, and are expected to complete, the study.  alidornase alfa is a plant cell expressed, chemically modified recombinant DNase enzyme resistant to inhibiti...